The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
April 16th 2024
Patients with atopic dermatitis (AD) may have an increased risk of headache disorder and migraines.
Dr Robert Sidbury on Psychosocial, Behavioral Issues Linked With Atopic Dermatitis
March 13th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, discussed the psychosocial and behavioral issues faced by patients with atopic dermatitis, particularly those with severe disease.
Watch
Skin Barrier Function in Moderate to Severe AD Significantly Improved With Dupilumab
March 9th 2022Dupilumab was shown to significantly improve factors of skin barrier function, including transepidermal water loss, lipid composition, and filaggrin, among patients with moderate to severe atopic dermatitis.
Read More
Multidisciplinary Approach Identifies Allergic, Immunology Burden in Severe AD
March 4th 2022Patients with severe atopic dermatitis showed significant associations with concomitant contact dermatitis and immune dysfunction after undergoing a multidisciplinary evaluation between allergy, immunology, and dermatology specialists.
Read More
Dr Robert Sidbury Discusses Utilization, Efficacy of Biologics for Atopic Dermatitis
February 24th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.
Watch
Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis
January 27th 2022Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Read More
Real-World Study Finds Dupilumab Safe, Effective for Moderate-to-Severe Atopic Dermatitis
January 6th 2022Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.
Read More
Dr David R. Stukus Spotlights Unmet Needs in Atopic Dermatitis Management
December 28th 2021David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.
Watch
Evaluating Differences in Therapeutic, Diagnostic Approaches to Atopic Dermatitis
December 24th 2021A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.
Read More
Dr David R. Stukus Discusses Access, Affordability Concerns of Emerging Atopic Dermatitis Therapies
December 22nd 2021David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Watch
Dupilumab Shows High Effectiveness in AD for Ages 6 Months and Up
December 18th 2021Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
Read More
Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis
December 17th 2021David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
Watch
Increased Risk of Fracture Found in Children With Atopic Dermatitis
December 7th 2021Children with atopic dermatitis were shown to be at an increased risk of fractures compared with the general population, with systemic use of corticosteroid and antihistamine therapy cited as mediating factors.
Read More
Dupilumab-Induced Ophthalmic Disease Common in Adults With Atopic Dermatitis
December 1st 2021More than 1 in 3 patients with atopic dermatitis reported incidence of dupilumab-induced ocular surface disease (DIOSD), with asthma and family history of AD shown to further increase the risk of developing DIOSD.
Read More